ORIGINAL ARTICLE
Clinical and instrumental peculiarities of the course of arterial hypertension in patients with cognitive function impairments
 
More details
Hide details
1
Medical and Social Assessment, Urgent and Ambulatory Care, First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia
 
 
Submission date: 2018-02-02
 
 
Acceptance date: 2018-02-02
 
 
Online publication date: 2018-03-16
 
 
Publication date: 2018-03-16
 
 
Electron J Gen Med 2018;15(4):em36
 
KEYWORDS
TOPICS
ABSTRACT
Objective:
Cognitive impairments (CIs) appear to be commonly encountered in patients with arterial hypertension (AH). Hence, our study was aimed at examining the frequency of cognitive impairments (CIs) in the physician’s outpatient practice, as well as at determining clinical and instrumental peculiarities of the course of AH in patients with and without CIs.

Method:
We carried out comprehensive examination of three hundred and fifty 50-to-80-year-old hypertensive patients followed up in the setting of a polyclinic and tested by means of neuropsychological scales (MMSE, Mini-Cog test, Montreal Cognitive Assessment Scale, Hospital Anxiety and Depression Scale), duplex scanning of extracranial vessels, and magnetic resonance tomography (MRT) of the brain.

Results:
The findings of neuropsychological testing demonstrated the presence of CIs in 83.5% of hypertensive patients, with CIs reaching the level of dementia in 16.9% and being combined with depressive symptoms in 40.3%. Hypertensive patients with CIs as compared with those without CIs were found to have more pronounced lesions to white matter of the brain: periventricular (71.1%) and/or subcortical (15.8%) leukoaraiosis. Subcortical leukoaraiosis of the frontal lobes of the brain was associated with an elevated level of systolic arterial pressure (SAP). It was confirmed that impaired circadian rhythm of AP with stable persistence of nocturnal hypertension resulted in the most pronounced structural and morphological damage of the brain.

Conclusion:
High incidence of CIs in hypertensive patients has been confirmed. Structural and morphological impairments of strategically important regions of the brain (subcortical leukoaraiosis of the frontal lobes) in hypertensive patients with CIs were associated with elevated SAP.

 
REFERENCES (26)
1.
Zakharov VV, Lokshina AV. Cognitive impairments in general clinical practice. Moscow. 2009; 8 [in Russian].
 
2.
Dadasheva MN, Kasatkin DS, Vishnyakova TI, et al. Cognitive impairments in patients with arterial hypertension: early diagnosis, possibilities of optimizing drug therapy. Consilium Medicum. 2011;13(9): 78-82 [in Russian].
 
3.
Levin OS. Cognitive impairment in therapeutic practice; cardiovascular diseases. Cons. Med. 2009;11(2): 55-61 [in Russian].
 
4.
Elias PK, D'Agostino RB, Elias MF, Wolf PA. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp. Aging. Res. 1995;21(4):393–417. https://doi.org/10.1080/036107....
 
5.
Anson O, Paran E. Hypertension and cognitive functioning among the elderly: an overview. Am. J. Ther. 2005;12 (4):359–65. https://doi.org/10.1097/01.mjt....
 
6.
Cacciatore F, Abete P, Ferrara N. et al. The role of blood pressure in cognitive impairment in an elderly population. J. Hypertens. 2002;15:135–42. https://doi.org/10.1097/000048....
 
7.
Shishkova VN. Effective solution of the problem of antihypertensive therapy in a patient with chronic cerebral ischaemia. Pharmatheca. 2013;18:97-101 [in Russian].
 
8.
Pedelty L, Nyenhuis DL. Vascular Cognitive Impairment. Current Treatment Options in Cardiovascular Medicine. 2006;8:243–50. https://doi.org/10.1007/s11936....
 
9.
Saxby BK., Harrington F, Wesnes KA. et al. Candesartan and cognitive decline in Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683–9. https://doi.org/10.1016/S1474-....
 
10.
Waldstein SR, Wendell CR. Neurocognitive function and cardiovascular disease. J. Alzheimers Dis. 2010;20(3):833–42. https://doi.org/10.3233/JAD-20....
 
11.
Odinak MM, Emelin AYu, Lobzin VYu, Kolcheva YuA. Therapy of vascular cognitive impairments. Russian Medical Journal. 2009;20:1295-7. [in Russian].
 
12.
Kearney-Schwartz A, Rossignol P, Bracard S. et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke. 2009;40:1229–36. https://doi.org/10.1161/STROKE....
 
13.
Rosenberg GA. Inflammation and white matter damage in vascular cognitive impairment. Stroke. 2009; 40: 20–3. https://doi.org/10.1161/STROKE....
 
14.
Yakhno NN., Zakharov VV. Mild to moderate cognitive impairments in old age: a lecture. Therapeutic Archives. 2006;1:80-3 [in Russian].
 
15.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L. еt al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–7. https://doi.org/10.1016/S0140-....
 
16.
Nazinyan AG. Vascular dementia and Alzheimer’s disease. Functional Diagnosis. 2006;3:64-8 [in Russian].
 
17.
Levin OS. Moderate cognitive impairment: diagnosis and treatment. Effective Pharmacology. Neurology and Psychiatry. 2012;5:14-20 [in Russian].
 
18.
Levin OS., Golubeva LV. Heterogeneity of moderate cognitive impairment: diagnostic and therapeutic aspects. Cons. Med. 2006;12:106-10 [in Russian].
 
19.
Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurology. 2004;3:246–8. https://doi.org/10.1016/S1474-....
 
20.
Petersen RS, Smith GE, Waring SC. et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56:303–8. https://doi.org/10.1001/archne....
 
21.
Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006;24:1907–14. https://doi.org/10.1097/01.hjh....
 
22.
Peila R, White LR, Masaki K, Petrovitch H, Launer. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37(5):1165–70. https://doi.org/10.1161/01.STR....
 
23.
Semplicini A, Amodio P, Leonetti G. et al. Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research. Pharmacol. Ther. 2006;109(1-2):274–83. https://doi.org/10.1016/j.phar....
 
24.
Waldstein SR, Wendell CR, Katzel LL. Hypertension and neurocognitive function in older adults: Blood pressure and beyond. In: Whitfield K.E., editor. Annual review of gerontology and geriatrics: Focus on biobehavioral perspectives on health in late life. New York, NY: Springer; 2010;115–34. https://doi.org/10.1891/0198-8....
 
25.
Zakharov VV. Medicamentous and non-medicamentous methods of correction of cognitive impairments. Consilium Medicum. Neurology/Rheumatology. 2014;2:24-9 [in Russian].
 
26.
Bagoly E, Fehér G, Szapáry L. The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv. Hetil. 2007;148(29):1353-8. https://doi.org/10.1556/OH.200....
 
eISSN:2516-3507
Journals System - logo
Scroll to top